Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
- 18 August 2025
- journal article
- review article
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (6) , e574-e576
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatmentClinical Research in Cardiology, 2024
- Patient Phenotype Profiling in Heart Failure with Preserved Ejection Fraction to Guide Therapeutic Decision Making. A Scientific Statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of HypertensionEuropean Journal of Heart Failure, 2023
- Heart Failure With Preserved Ejection FractionJAMA, 2023
- Iron deficiency and cardiovascular diseaseEuropean Heart Journal, 2022
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine, 2021
- Role of iron metabolism in heart failure: From iron deficiency to iron overloadBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ, 2016
- Iron Therapy for the Treatment of Iron Deficiency in Chronic Heart Failure: Intravenous or Oral?European Journal of Heart Failure, 2015
- Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiencyEuropean Heart Journal, 2014
- Ferric Carboxymaltose in Patients with Heart Failure and Iron DeficiencyNew England Journal of Medicine, 2009